INVO Fertility (NASDAQ:IVF) Upgraded at Maxim Group

Maxim Group upgraded shares of INVO Fertility (NASDAQ:IVF) from a hold rating to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

INVO Fertility Trading Down 5.5%

IVF stock opened at $1.04 on Tuesday. The stock has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $5.04. INVO Fertility has a 1 year low of $0.71 and a 1 year high of $120.93. The stock has a market cap of $2.49 million, a PE ratio of 0.00 and a beta of 2.65.

Hedge Funds Weigh In On INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC bought a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility as of its most recent filing with the Securities & Exchange Commission. 12.02% of the stock is owned by hedge funds and other institutional investors.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.